| 0.2079 0.004 (1.76%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.29 | 1-year : | 0.33 |
| Resists | First : | 0.25 | Second : | 0.28 |
| Pivot price | 0.22  |
|||
| Supports | First : | 0.19 | Second : | 0.16 |
| MAs | MA(5) : | 0.2 |
MA(20) : | 0.23 |
| MA(100) : | 0.26  |
MA(250) : | 0.73 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.9 |
D(3) : | 9.6 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 1.97 | Low : | 0.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PIRS ] has closed above bottom band by 29.7%. Bollinger Bands are 29.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.21 - 0.21 | 0.21 - 0.21 |
| Low: | 0.2 - 0.2 | 0.2 - 0.2 |
| Close: | 0.21 - 0.21 | 0.21 - 0.21 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Tue, 14 Nov 2023
Pieris Pharmaceuticals: Q3 Earnings Snapshot - San Francisco Chronicle
Wed, 08 Nov 2023
North American Morning Briefing: Stock Futures -2- - Morningstar
Mon, 25 Sep 2023
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why - Nasdaq
Thu, 24 Aug 2023
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive ... - Yahoo Finance
Wed, 23 Aug 2023
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What ... - Yahoo Finance
Fri, 18 Aug 2023
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 14.9 (%) |
| Held by Institutions | 67.9 (%) |
| Shares Short | 186 (K) |
| Shares Short P.Month | 573 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | -59.3 % |
| Operating Margin | 15.8 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | -84.7 % |
| Qtrly Rev. Growth | 263.5 % |
| Gross Profit (p.s.) | -0.28 |
| Sales Per Share | 0.47 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -0.62 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0.43 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|